The F105 mAb, identified in an HIV-1-infected individual, binds to a discontinuous epitope on the HIV-1 gpl20 envelope glycoprotein, blocks the binding of gpl20 to the CD4 viral receptor, and neutralizes a broad range of HIV-1 isolates. This study reports the primary nucleotide and deduced amino acid sequences of the rearranged heavy and light chains of the mAb For both chains, the mutational pattern in the rearranged V H and V L genes is indicative of an antigen-driven process. These studies show that production of a broadly neutralizing anti-HIV-1 antibody that recognizes determinants within the CD4 recognition site ofthe envelope glycoprotein is achieved by rearrangement of the V714 and Humvk325 germline variable region genes along with selected individual point mutations in the rearranged genes. (J. Clin. Invest. 1992. 90:1467-1478
Introduction
HIV-1 productively infects human CD4+ cells, including CD4+ T cells and cells of the monocyte/macrophage lineage (1) (2) (3) (4) (5) . The first step in infection by HIV-1 is the specific binding ofgp 120, the envelope glycoprotein ofHIV-l, to its cellular receptor, the CD4 molecule (6, 7) . Infection with HIV-l leads, in most cases, to a progressive decline in the number and functions of CD4+ T cells with the eventual appearance of clinical manifestations ofcellular immunodeficiency, such as opportunistic infections and malignancies, i.e., AIDS (8) .
Serum antibodies reacting with the HIV-1 gp 120 can neutralize viral infection by binding to several sites on the molecule (9, 10) . The earliest neutralizing human antibody re-sponse is directed to epitopes in the third hypervariable region of gpl 20, the principle neutralizing domain, which is contained within a loop formed by disulfide bonding (11) (12) (13) . These antibodies are frequently strain specific (14) . Envelope glycoprotein variation both within the linear epitope and outside the epitope can allow escape ofviruses from neutralization by these antibodies (15, 16) . Later in the course of HIV-1 infection, more broadly neutralizing antibodies appear (17) . A large fraction of these broadly neutralizing antibodies, which are present in low concentrations in patients' sera, are directed to conformationally sensitive epitopes on gpl 20 (18, 19) . A subset ofthe broadly reactive antibodies, found in the serum of patients, interferes with the binding of gpl 20 and CD4 (10, (20) (21) (22) . These antibodies appear to be reactive with a discontinuous epitope on gpl 20 that encompasses the CD4 binding region (23, 24) . This region of gp120 is well conserved although not invariant.
Several human mAbs derived from HIV-infected individuals, which block CD4 binding, recognize conformation-dependent epitopes on gp120, and neutralize a broad range of HIV-1 isolates, have recently been described (25) (26) (27) . One of these human mAbs is Fl05 (25) . This IgGjk antibody reacts with a conformationally defined epitope on HIV-1/gp120, which appears to be within or topographically near the CD4-binding site (24, 25) . This mAb recognizes an epitope on the surfaces of HIV-1-infected malignant T cell and monocyte cell lines and on intact virions. In addition, Fl05 neutralizes a number ofdiverse HIV-l isolates, including IIIB, MN, RF, and SF2 strains (25) . This antibody is potentially useful in immunoprophylaxis after exposure, in preventing the vertical transmission of HIV, and in monitoring the humoral immune response in HIV-1-infected individuals and vaccinated volunteers.
One ofthe aims ofelucidating nucleotide sequences ofantibodies specific for a single antigen is to determine the extent of diversity or restriction in the use of germ line genes (28). Recently, the primary nucleotide and deduced amino acid sequences of several human anti-gpl 20 V3 loop and anti-gp41 heavy chains have been reported (29, 30) . To understand the molecular nature ofthe broadly neutralizing human antibodies that are directed at or near the CD4-binding domain ofgp 120, the rearranged heavy and light chains of the Fl05 mAb were cloned. These studies provide the first molecular characterization of the broadly neutralizing anti-gp120 antibodies and form the basis for future molecular studies aimed at investigating the humoral immune response to the CD4-binding domain of gp 120.
Methods
EBV transformants with the HMMA2.1 lTG/0 cell line, a nonsecreting human-mouse myeloma analogue (25) . Both cell lines were used for cDNA synthesis and polymerase chain reaction (PCR)' amplification experiments. First strand cDNA was synthesized in a 25-M1 reaction from 5 Atg of total RNA by using oligo(dT) priming and the Moloney murine-leukemia virus reverse transcriptase according to published protocols (31). 5-10% of the first strand cDNA was used to perform the PCR reactions. The temperatures used for the PCR are melt 940C, 1 min; primer anneal 520C, 2 min; primer extension 720, 2 min. 1-min ramp times were used except a 2-min ramp time was used between annealing and extension. Ethidium bromide-stained 2% agarose gels were use to separate the PCR fragments. The appropriate band was excised, gene cleaned (Bio 101, Inc., La Jolla, CA), Klenow repaired, restriction enzyme digested and cloned into pSLl 180 (Pharmacia LKB Biotech. Inc., Piscataway, NJ) using SURE bacteria (Stratagene Inc., La Jolla, CA) as hosts. At least three separate transformants were sequenced using both forward and reverse sequencing primers. DNA sequence analysis was performed by the method of Sanger et al. (32) . The sequencing primers were designed to be complementary to the polylinker sequences of pSLl 180.
The heavy chain primer pair consists ofa VH primer and a JH or CHI primer, each containing convenient restriction sites for cloning. The Kabat database on immunoglobulins was used to analyzed the amino acid and codon distribution found in the six distinct human VH families (33) . Based on this analysis, the 35-bp universal 5' VH primer was designed TTTGCGGCCGCTCAGGTGCA(G/A)CTGCTCGAGTC-(T/C)GG, which is degenerate for two different nucleotides at two positions and will anneal to the 5' end of FRI sequences. A A was designed to anneal to the most 3' kappa constant region nucleotides and this region is followed by two stop codons and a BamHI cloning site. After the primary nucleotide sequence was determined for both the F105 heavy and kappa chain genes and the germ line genes were identified, PCR primers were designed based on the leader sequences of the VH 71-4 (35) and Humvk325 (36) germ line genes. The VH71-4 leader primer TTTACCATGGAACATCTGTGGTTC and the Humvk325 leader primer GGAACCATGGAAACCCCAGCGCAG both contain a 5' NcoI site (underlined). These leader primers were used in conjunction with the respective C region primers for PCR amplification experiments.
ELISA. F105, or IgM ODO (agift from Dr. Gregg Silverman, University of California, San Diego, CA) were resuspended in coating buffer (100 mM sodium carbonate, pH 8.5) at 150 ng/ml and incubated overnight (100 Al/ well) at 40 on ELISA plates (Immulon No. 1; Dynatech Labs, Inc., Chantilly, VA). After washing with Tris-buffered saline containing 0.2% Tween 20 (TBS-T) and blocking with TBS-T containing 1% BSA, the plates were incubated at varying concentrations with various rabbit anti-peptide antisera that recognize VH III or IV framework or VH IV CDR2 determinants (37) . A rabbit antisera raised against an unrelated peptide served at a negative control (rabbit anti-formyl Met-Leu-Phe/BSA). In some cases CDR2 peptides were preincubated at 1 Ag/ml with anti-CDR2 peptide antisera for 1 h at room temperature before addition to the plate. After overnight incubation the plates were washed extensively and bound rabbit antibody was detected with affinity column-purified, alkaline phosphatase-coupled goat anti-rabbit IgG that had been absorbed with human serum ( Antibody was tested against each cell at 22°C, 18°C, and 4°C. Reactions were tested by both direct hemagglutination and also using mouse monoclonal anti-human IgG (Coombs sera). For rheumatoid factor activity, various dilutions of F105 were mixed with human IgG-coated latex particles and assayed for agglutination.
Results
F105 heavy chain VH gene is derived from germ line VH IV 71-4. The F105 hybridoma cell line was used as the source of mRNA. First strand cDNA was prepared by the method of Gubler and Hoffman (31 ) and 5-10% ofthis reaction mixture was used in the PCR experiments. The degenerate VH and JH primers were initially used to amplify by PCR an 370-nucleotide fragment. This is the expected molecular weight ofthe rearranged heavy chain gene. This amplified DNA was inserted into the pSLl 180 plasmid. Subsequent to the identification of the germ line VH gene, the cDNA was reamplified using primers that recognize the leader and IgG, constant regions to obtain unbiased DNA sequence information ofthe FR1 and JH regions.
DNA sequence analysis was performed by the method of Sanger et al. (32 CDR1 and CDR2 regions. At the amino acid level, four of the F105 VH nucleotide changes result in silent mutations that are distributed equally in each of the three FR regions (positions 26,FR1; 49,FR2; 94,FR3) and there is one silent mutation in CDR2 (position 52) . The remaining eight nucleotide changes result in amino acid changes that occur in the three FRs more frequently than in the CDRs (Table II) . Two nonconservative changes occur in the FR2 region and three conservative changes occur in the FR3 region. One additional FRI region framework residue at position 29, which results in a conservative change valine to isoleucine, is located immediately adjacent to the complementarity determining region (CDR) defined by Kabat et al. (33) . This region may also contribute to the topography of the antibody-combining site (39) . The presence of isoleucine at position 29 in four of seven germ line VH IV genes suggests that isoleucine may represent an allelic difference and not a somatic mutation (35, 38) . In the CDR regions, two changes occur with a non-conservative replacement of tyrosine to histidine in CDR1, position 32 and a semiconservative change of asparagine to serine in CDR2, position 60. The ratio ofsubstitution to silent mutations is 2:1. The substitution mutations occur in a FR/CDR ratio of 3:1.
Comparative analysis of FJO5 VH and other VH 71-4-derived rearranged VH genes. 
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100E100F101 changes, may represent allelic differences in the da4/da 1 germ line genes rather than somatic mutations. (37) used peptide antisera raised against consensus peptides from the first framework (FR 1) and second CDR region (CDR2) of human VH IV heavy chains to make heavy chain class assignments for cold agglutinin and rheumatoid factor antibodies (37, 50) . The CDR2 consensus peptide HV2a for these antibodies could not distinguish among three different VHIV germ line genes (V7 1-2, V7 1-4, and V79) (37) . The results demonstrated that both cold agglutinin and a subgroup of rheumatoid factor heavy chains both reacted with FRl antibodies but only cold agglutinin antibodies reacted with anti-VH4-HV2a antisera. Fig. 1 illustrates ELISA experiments with F105 and the cold agglutinin IgM ODO. The anti-VH4-FRI antisera reacts strongly with both Fl05 and IgM ODO whereas anti-VH3-FRlI antisera shows only background activity compared with the unrelated rabbit antiformyl-MetLeu-Phe antisera. Fl05 also reacts with anti-VH4-HV2a, albeit weakly, and this binding is inhibited by preincubation of anti-VH4-HV2a with VH4-HV2a peptide and to a lesser extent with the closely related VH4-2c peptide. This result indicates that the Ft05 VH is structurally more closely related to the cold agglutinin heavy chains than to the rheumatoid factor heavy chains. or IgM ODO were incubated overnight on ELISA plates. After blocking with TBS-T with 1% BSA, the plates were incubated with various rabbit anti-peptide antisera ( 1:1500 final dilution) that recognize VH III or IV framework or VH IV CDR2 determinants (37) . A rabbit antisera raised against an unrelated peptide served at a negative control (rabbit antiformyl Met-Leu-Phe/BSA). In some cases CDR2 peptides were preincubated at 1 Ag/ml with anti-CDR2 peptide antisera for 1 h at room temperature before addition to the plate. Bound rabbit antibody was detected with affinity column-purified, alkaline phosphatase-coupled goat anti-rabbit IgG that had been absorbed with human serum. Absorption at 405 nm was recorded. Data represent mean of triplicate determinations±SD. *P < 0.01 compared with anti-VH3FR I or anti-fM LF using Student's two-tailed t test.
(A) IgM ODO-coated plates; (B) F105-coated plates.
to those used for the heavy chain. The degenerate Vkpp. and Jkappa primers were initially used to amplify by PCR an 350-nucleotide fragment. This is the expected molecular weight of the rearranged kappa light chain gene. This amplified DNA was inserted into the pSL1 180 plasmid. Subsequent to the identification ofthe germ line Vka. gene, the cDNA was reamplified using primers that recognize the leader and kappa chain constant regions to obtain unbiased DNA sequence information of the FRI and Jkpp. regions.
DNA sequence analysis revealed that the rearranged F105 Vk gene is derived from a member of the Vk III subgroup gene family (33) . The Vk III subgroup can be further subdivided into sub-subgroups, one of which is the Vk Tub sub-subgroup. F105 shares the greatest sequence similarity with the Vk IlIb germ line gene Humvk325 (97.7%, 343/351 nucleotides) (Table VI, A). There are a total ofnine nucleotide changes in F 105 Vk compared with Humvk325 (Table II) . Two of the changes, which are both transversions, are located in the framework regions FRI and FR3. Seven additional changes, including four transitions and three transversions, are located in CDR1 (one) and CDR3 (six).
At the amino acid level, only two ofthe nucleotide changes result in a silent mutations. Ofthe remaining seven nucleotide changes, two changes occur in framework regions and five occur in the CDR regions (Table II and Table VI, B) . The two framework changes include a nonconservative change at position 15 in FRI and a conservative change at position 78 in FR3. In the CDR regions, one change occurs with a nonconservative substitution at position 31 in CDR1. There are three nonconservative amino acid changes in CDR3 in positions 92, 94, and 95. The change at position 95 (proline to valine) is the result of two individual point mutations that occur in one codon. The ratio of substitution to silent mutations is 7:2 and these changes occur in a FR/CDR ratio of 2:7. This pattern of changes is in marked contrast to the pattern of changes observed for the F105 VH sequence where the ratio ofsubstitution to silent mutations is 2:1 and the substitution mutations occur in a FR/CDR ratio of 3:1 (Table II) .
Analysis ofthe F105 Jk region gene. The F105 J. region is most similar to the germ line J 2gene (Table VI, The mutational pattern in the rearranged VH and VL genes is indicative of an antigen-driven process. For F105 VH the ratio of substitution to silent mutations is 2:1. These substitution mutations occur in a FR/CDR ratio of 3:1. This type of change involving a high number of amino acid substitutions in the FR regions has been attributed to stochastic rather than selective forces since antigen-driven selective forces would be expected to impose higher selection pressure on the CDR regions. It is possible that selection has occurred but has acted to retain CDR 1 and 2 in near germ line configuration, whereas more divergence is allowed in the FR regions where these residues may play a role in antigen binding (53). It is also possible that these FR mutations may play a role in network regulation, i.e., are selected by necessity of idiotypic regulation in the antigpl20 response (54) . However, changes in the VH gene segment must be considered in the context of the overall selection forces that act on the heavy chain. The power of antigen selection can make D-D fusions, a relatively rare event in B cell development, which occur at a lower frequency than normal joining, biologically significant (43) . In addition, heavy chain selection may be biased to changes in CDR3 since four of five amino acid changes occur in the JH5 gene and these changes are concentrated in the 5' end of the gene, which contributes to the formation of CDR3 (Table V) . For the F105 kappa chain, the ratio of substitution to silent mutations is 7:2 and these mutations occur in a FR/CDR ratio of 2:7. This is in marked contrast to the mutational pattern seen with F105 VH (Table III) and strongly supports the notion that these somatic changes are the result of an antigen-driven process. Most notable are the higher number of mutations in CDR3 than are generally found when compared with cloned Humvk325-derived light chain genes from patients with chronic lymphocytic leukemia (55), small cell non-Hodgkin's lymphoma (56) , monoclonal rheumatoid factors (51) , and Sjogren's syndrome (57) . These somatic mutations could reflect the chronic B cell activation that occurs both in the regional lymph nodes and peripheral blood of patients with AIDS (58) .
The F105 VH gene is derived from a member of the VH IV gene family, VH 71-4. This is a relatively small family with -10 members. The expression ofVH IV genes in humans has been described only recently; indeed, the heavy chain families, VH IV, V, and VI were identified only in the last five years (35) . Expressed VH IV genes have been found at an unexpectedly high frequency in human autoantibodies (28, 40, 53, (59) (60) (61) . Only a few of these antibodies have been shown to use the VH 71-4 germ line gene (Table V) (59, 62) . The most studied ofthe VH IV-derived heavy chain genes include the cold agglutinin and rheumatoid factor antibodies. Several laboratories have determined that cold agglutinins use the VHIV 2-1 germ line gene segment (53, 62-64) whereas a subgroup ofautoantibodies of the IgM anti-IgG type (rheumatoid factors) use members of a VH IV gene family that is serologically distinct from the cold agglutinin VH IV 2-1-derived genes (50) . The molecular characterization of these VH IV rheumatoid factor heavy chains has not been reported. Our studies demonstrate that the VH4-HV2a idiotope is expressed, albeit weakly, on the F105Vk neu F105 heavy chain. The weak binding may be the result of the asparagine to serine substitution in position 60. Accordingly, by this type of antiidiotypic analysis the F105 VH is more closely related structurally to the VH IV heavy chains of anti-I cold agglutinin antibodies than to the VH IV heavy chains of the rheumatoid factor antibodies. However, in spite of this structural similarity, F105 displays neither cold agglutinin nor rheumatoid factor activity (data not shown).
Restricted heavy and light chain V gene use occurs in several autoimmune (57, 63, 65) and infectious diseases (66) (67) (68) . Restricted V gene use in response to gp 120 is highly suggested by several recent observations with antiidiotypic antibodies (69, 70) , however, only limited anti-gp 120 sequence data are available at present for comparison with F105. Andris et al. (29) recently reported the heavy chain nucleotide sequences of two human anti-gp 120 V3 loop and two anti-gp41 mAbs that were produced by EBV transformation of peripheral blood cells of HIV-infected patients. Their analysis showed that one ofthe anti-V3 loop antibodies (268-D) (Table III) used the VH 71-4 germ line gene whereas the other anti-V3 loop antibody (257-D) used a VH V germ line gene VH25 1. Both of the antigp41 antibodies (120-16 and 98-6) used VH IV germ line genes, VH 71-2 and VH 2-1, respectively. The predominance of VH IV genes in these examples is evident. Additional sequence data will be required to identify any restricted use ofV region genes.
The V region of the Ft05 light chain appears to be derived from the Humvk325 germ line gene and is a member of the VkIIIb sub-subgroup. The phenotypic marker of the human germ line gene Humkv325 is the 17.109 cross-reactive idiotype (36, 71, 72) as defined by a murine mAb that was raised against human rheumatoid factor (73). The 17.109 cross-reactive idiotype is expressed by -2% of circulating IgM from normal adults (74) . In addition to the aforementioned occurrence of Humkv325 light chains in monoclonal rheumatoid factors (51) , in B cell malignancies, including chronic lympocytic leukemia (55) and small cell non-Hodgkin's lymphoma (56) , and in lymphocytes from biopsy specimens of patients with primary Sjogren's syndrome (57), Humkv325 light chains have also been detected in non-rheumatoid factor paraproteins and in antibodies with anti-LDL, anti-intermediate filament, and anti-DNA histone activity (51, 52, 72 (75) . The human anticytomegalovirus antibody EV 1-15 has also been shown to use a VkIIIb light chain that is probably derived from Humvk325 (76) . In the peripheral blood of HIV-infected patients with AIDS, resting B cells appear to be lacking, and there are both decreased numbers of partially activated cells and increased numbers of fully differentiated B cells (58) . The polyclonal B cell activation seen in these AIDS patients may be due to concomitant EBV or cytomegalovirus infections, which are often seen in these patients, or may be due to a direct effect of HIV (58) . Whether this polyclonal B cell activation that is seen in HIV-infected patients is manifested by a increased frequency of 17.109 cross-reactive idiotype expression cannot be answered by the present study but represents an important avenue for future investigations.
The adult repertoire of antibody specificities is acquired in a developmentally programmed fashion (77). Schroeder et al. (77) and Kipps et al. (78) have demonstrated that rearranged VH 71-4 genes (V58P2 and V37P1 ) and the 17.109 cross-reactive idiotype are expressed in fetal tissue, respectively. Since the restricted use of VH genes may limit immunocompetence in fetal and neonatal life (77) , it will be of importance to determine if the anti-gpl 20 antibodies produced by these neonatal and pediatric HIV-infected patients, in particular those antibodies that recognize determinants within the CD4 recognition site of gp 120, use these same V region germ line genes with or without somatic mutations.
